Abstract: Disclosed herein are recombinant antibodies exhibiting binding affinity to CD47 polypeptide. According to some embodiments of the present disclosure, the recombinant antibodies are capable of blocking the interaction of CD47 and signal receptor protein-alpha (SIRP?). Accordingly, also disclosed herein are pharmaceutical compositions comprising the recombinant antibodies, and uses thereof in the treatment CD47-related diseases.
Type:
Application
Filed:
April 22, 2022
Publication date:
November 3, 2022
Applicant:
AnTaimmu BioMed Co., Ltd.
Inventors:
San-Tai SHEN, Yueh-Liang TSOU, Jen-Chieh LIN, Chia-Chi LIU
Abstract: The present invention provides binding molecules, including monoclonal antibodies, multi-specific antibodies, and antibody fragments, that specifically bind to the coronavirus, such as SARS-CoV-2, and methods of use thereof. In some aspects of the invention, the binding molecules are human antibodies, fragments, or derivatives thereof that specifically bind to SARS-CoV-2 spike protein. In some aspects of the invention, the binding molecules function to neutralize SARS-CoV-2. The present invention also relates to methods of using the binding molecules and compositions for diagnosis and treatment.
Type:
Application
Filed:
January 12, 2022
Publication date:
July 21, 2022
Applicant:
Antaimmu BioMed Co., Ltd.
Inventors:
San-Tai Shen, Ing-Chien Chen, Kuang-Kai Liu, Frederick Y. Luh
Abstract: Disclosed herein is a recombinant antibody against the nucleocapsid protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A kit containing the recombinant antibody for use in coronavirus detection is encompassed in the present disclosure. Also disclosed herein are in vitro methods of detecting coronavirus infection in a subject with the aid of the recombinant antibody.